Lenalidomide Generis

Lenalidomide, the active ingredient in Lenalidomide Generis, is an immunomodulatory drug (IMiD) presented as an oral formulation for systemic use. It is employed in the treatment of certain blood cancers, notably multiple myeloma and myelodysplastic syndromes, in adult patients.

GNH USA supplies Lenalidomide Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide acts on malignant plasma cells and dysplastic bone‑marrow clones, providing therapeutic benefit in specific hematologic malignancies. - Multiple myeloma: improves progression‑free survival and overall response rates. - Myelodysplastic syndromes: reduces transfusion dependence and delays transformation to acute leukemia. - Relapsed or refractory multiple myeloma: offers an additional line of therapy after prior treatments have failed.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools occurring intermittently. - Nausea: mild to moderate upset stomach. - Rash: skin erythema or itching. - Cytopenias: reduced blood cell counts, especially neutrophils and platelets. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophil count increasing infection risk. - Hepatotoxicity: elevated liver enzymes indicating liver injury. - Secondary malignancies: emergence of new cancers. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction. - Cardiac arrhythmias: irregular heart rhythms requiring monitoring.

Before initiating therapy, clinicians should assess patient history and baseline laboratory values. - Pregnancy: contraindicated; category X due to teratogenic risk. - Thrombosis risk: evaluate need for prophylactic anticoagulation. - Renal impairment: adjust monitoring for patients with reduced kidney function. - Hepatic dysfunction: monitor liver enzymes regularly. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Lenalidomide may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increase bleeding risk. - Immunosuppressants: may exacerbate cytopenias.

Moderate Interactions (Monitor Closely): - NSAIDs: can worsen renal function. - Antihypertensives: may require dose adjustment due to fluid shifts. - Vaccines: live vaccines should be avoided during treatment.